Coya Therapeutics (COYA) Competitors $6.38 -0.31 (-4.63%) Closing price 04:00 PM EasternExtended Trading$6.37 -0.01 (-0.16%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock COYA vs. PRTA, ITOS, SLDB, REPL, ESPR, CYRX, IVA, CMPX, AUTL, and IMABShould you be buying Coya Therapeutics stock or one of its competitors? The main competitors of Coya Therapeutics include Prothena (PRTA), iTeos Therapeutics (ITOS), Solid Biosciences (SLDB), Replimune Group (REPL), Esperion Therapeutics (ESPR), CryoPort (CYRX), Inventiva (IVA), Compass Therapeutics (CMPX), Autolus Therapeutics (AUTL), and I-Mab (IMAB). These companies are all part of the "pharmaceutical products" industry. Coya Therapeutics vs. Its Competitors Prothena iTeos Therapeutics Solid Biosciences Replimune Group Esperion Therapeutics CryoPort Inventiva Compass Therapeutics Autolus Therapeutics I-Mab Prothena (NASDAQ:PRTA) and Coya Therapeutics (NASDAQ:COYA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends. Is PRTA or COYA more profitable? Coya Therapeutics has a net margin of 0.00% compared to Prothena's net margin of -2,929.30%. Coya Therapeutics' return on equity of -61.05% beat Prothena's return on equity.Company Net Margins Return on Equity Return on Assets Prothena-2,929.30% -62.17% -54.43% Coya Therapeutics N/A -61.05%-53.61% Which has stronger earnings & valuation, PRTA or COYA? Coya Therapeutics has lower revenue, but higher earnings than Prothena. Coya Therapeutics is trading at a lower price-to-earnings ratio than Prothena, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProthena$135.16M3.27-$122.31M-$5.64-1.46Coya Therapeutics$3.55M30.07-$14.88M-$1.24-5.15 Does the media favor PRTA or COYA? In the previous week, Prothena had 7 more articles in the media than Coya Therapeutics. MarketBeat recorded 12 mentions for Prothena and 5 mentions for Coya Therapeutics. Coya Therapeutics' average media sentiment score of 0.69 beat Prothena's score of 0.48 indicating that Coya Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prothena 5 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Coya Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals hold more shares of PRTA or COYA? 97.1% of Prothena shares are held by institutional investors. Comparatively, 39.8% of Coya Therapeutics shares are held by institutional investors. 9.2% of Prothena shares are held by company insiders. Comparatively, 12.0% of Coya Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has more risk and volatility, PRTA or COYA? Prothena has a beta of -0.04, indicating that its stock price is 104% less volatile than the S&P 500. Comparatively, Coya Therapeutics has a beta of 0.26, indicating that its stock price is 74% less volatile than the S&P 500. Do analysts rate PRTA or COYA? Prothena presently has a consensus target price of $19.75, suggesting a potential upside of 140.56%. Coya Therapeutics has a consensus target price of $16.50, suggesting a potential upside of 158.62%. Given Coya Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Coya Therapeutics is more favorable than Prothena.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Prothena 1 Sell rating(s) 4 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.33Coya Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryCoya Therapeutics beats Prothena on 11 of the 14 factors compared between the two stocks. Get Coya Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for COYA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding COYA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart COYA vs. The Competition Export to ExcelMetricCoya TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$111.89M$3.12B$5.76B$9.91BDividend YieldN/A2.28%6.66%4.49%P/E RatioN/A21.0283.0126.65Price / Sales30.07379.56503.05163.66Price / CashN/A43.5325.7028.92Price / Book2.698.1210.796.52Net Income-$14.88M-$53.35M$3.29B$266.21M7 Day Performance-4.92%0.05%0.01%-0.76%1 Month Performance0.63%7.08%7.06%3.83%1 Year Performance9.62%11.92%50.09%24.39% Coya Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)COYACoya Therapeutics2.6924 of 5 stars$6.38-4.6%$16.50+158.6%+9.3%$111.89M$3.55M0.006News CoverageAnalyst ForecastPRTAProthena3.3413 of 5 stars$8.35-0.4%$30.25+262.3%-60.5%$449.48M$135.16M-1.48130News CoverageAnalyst ForecastITOSiTeos Therapeutics3.5091 of 5 stars$10.13flat$15.50+53.0%N/A$447.85M$35M-2.1790News CoveragePositive NewsShort Interest ↓SLDBSolid Biosciences3.6748 of 5 stars$5.71+2.0%$15.00+162.7%-32.1%$444.64M$8.09M-2.04100News CoveragePositive NewsREPLReplimune Group4.2285 of 5 stars$5.68+3.5%$7.67+35.0%-42.7%$443.38MN/A-1.75210Trending NewsGap DownESPREsperion Therapeutics3.8844 of 5 stars$2.19+1.9%$7.00+219.6%+32.8%$441.55M$332.31M-4.47200Options VolumeCYRXCryoPort4.4265 of 5 stars$8.79-0.2%$12.00+36.5%-2.0%$440.12M$228.38M6.611,186News CoveragePositive NewsIVAInventiva2.742 of 5 stars$4.59-1.7%$10.40+126.6%+148.2%$439.09M$9.20M0.00100News CoverageAnalyst ForecastShort Interest ↑Gap DownCMPXCompass Therapeutics2.696 of 5 stars$3.15+4.3%$12.89+309.2%+123.2%$435.58M$850K-7.0020News CoverageAUTLAutolus Therapeutics3.0573 of 5 stars$1.61+0.6%$9.12+466.5%-62.6%$428.49M$10.12M-1.92330Positive NewsIMABI-Mab2.3627 of 5 stars$5.18+7.5%$6.50+25.5%+342.9%$423.00MN/A0.00380Short Interest ↑Gap Up Related Companies and Tools Related Companies Prothena Competitors iTeos Therapeutics Competitors Solid Biosciences Competitors Replimune Group Competitors Esperion Therapeutics Competitors CryoPort Competitors Inventiva Competitors Compass Therapeutics Competitors Autolus Therapeutics Competitors I-Mab Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:COYA) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMusk Warns. Trump Acts. Your Retirement May Depend on ItWith Donald Trump back in the White House, many believe an economic revival could be underway — but it also br...American Alternative | Sponsored“HELIOS”: My No. 1 Investment of the 2020sA mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druck...Stansberry Research | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredTrump’s national nightmare is hereWashington just added $1 trillion to the national debt in less than two months — an astonishing pace of spendi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coya Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Coya Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free COYA Stock Alerts